Chengdu New Radiomedicine Technology
Chengdu New Radiomedicine Technology develops medical isotopes and radiopharmaceuticals like Yttrium-90 and Lutetium-177 to address supply bottlenecks.
Secondary Market Price
How Chengdu New Radiomedicine Technology Measures Up
To help you manage your Chengdu New Radiomedicine Technology equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Chengdu New Radiomedicine Technology's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Chengdu New Radiomedicine Technology Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Chengdu New Radiomedicine Technology's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Chengdu NRT Medical Technology Co., Ltd. is a company engaged in the research, development, production, and supply of medical isotopes and radiopharmaceuticals. Its current activities are centered on securing a reliable supply of medical isotope raw materials and developing innovative radiopharmaceuticals for patients in China and globally. The company's product line includes Yttrium-90 carbon microsphere injection, a Germanium-68/Gallium-68 generator, Lutetium-177 chloride solution, and Actinium-225 nitrate solution. Established in 2016, the company has operated with a strategy to overcome isotope supply bottlenecks while advancing the development of radiopharmaceutical drugs.
Recent developments indicate an expansion of the company's industrial capacity, with the launch of industrialization projects for medical isotopes and drugs in Hengyang and Fuzhou. In late 2025, the company was recognized as a 'Sichuan Provincial Enterprise Technology Center' and also completed the first subject enrollment for Phase I clinical trials of its 68Ga-NRT6020 and 177Lu-NRT6020 injections. In early 2026, a public announcement was made regarding the environmental impact assessment draft for the Hengyang industrialization project, signaling progress in its development.
- Shenzhen Capital Group
- PICC Capital
- China Nuclear Industrial Fund
- Wuxi AstraZeneca CICC Venture Capital
- Zhongqi Capital
- Guangdong Traditional Chinese Medicine Health Equity Investment Fund
- Nuclear Power High Tech
- Hunan Chasing Fund
- Chengdu Aerotropolis Innovation & Venture Capital
- BTG International Asia
- Boston Scientific
- Hangzhou Ruizhao
- Ningbo Zhongchao Investment
- Co-Founder, Jiming Cai
- Co-Founder, Maoliang Li
- Co-Founder, Jihui Qian
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Chengdu New Radiomedicine Technology worth joining?
Deciding to join involves weighing many factors, including the potential upside of your equity compensation. Platforms like Prospect can help you model the potential value of your equity and compare it to other opportunities to make an informed decision.
What should I do with my Chengdu New Radiomedicine Technology stock?
Managing your startup stock involves creating a strategy for exercising options and selling shares that aligns with your financial goals and minimizes your tax burden. Prospect offers personalized option exercise strategies and tax planning to help you get the most out of your equity.
Can you sell Chengdu New Radiomedicine Technology stock?
As a private company, selling your stock is typically limited to specific events like tender offers or transactions on secondary markets, if the company permits them. Tools from Prospect can help you decide how much to sell during a tender offer and determine which shares are the most tax-optimal to part with.
How can I find the value of my Chengdu New Radiomedicine Technology stock?
Valuing stock in a private company is complex, as it isn't publicly traded and its worth is based on factors like the last funding round and internal 409A valuations. To get a clearer picture, Prospect uses machine learning models to project a likely range of outcomes for your equity's value.
What is Chengdu New Radiomedicine Technology's equity worth?
The total value of your equity depends on the company's future performance, and for a private company, this value is an estimate rather than a fixed number. By analyzing your specific holdings and using predictive models, Prospect can provide personalized projections to help you understand what your equity could be worth.
What is Chengdu New Radiomedicine Technology's stock ticker symbol?
Since Chengdu New Radiomedicine Technology is a private company, it does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they become publicly traded on a stock exchange.
Can I buy or sell Chengdu New Radiomedicine Technology stock?
Buying stock is generally restricted to accredited investors during funding rounds, while selling is possible during specific windows like tender offers or on secondary markets. Prospect provides tools and strategies to help you make informed decisions about when to exercise options and how to sell shares for optimal tax efficiency.
What is the criteria to buy or invest in Chengdu New Radiomedicine Technology stock?
Investing in a private company like Chengdu New Radiomedicine Technology is usually limited to venture capital firms and accredited investors who participate in funding rounds. For employees, platforms like Prospect offer data-driven models and analysis to help evaluate the equity you receive as part of your compensation.
